WO2003095647A3 - CHIMERIC snRNA MOLECULES CARRYING ANTISENSE SEQUENCES AGAINST THE SPLICE JUNCTIONS OF THE DYSTROPHIN GENE AND THEIR THERAPEUTIC APPLICATIONS - Google Patents

CHIMERIC snRNA MOLECULES CARRYING ANTISENSE SEQUENCES AGAINST THE SPLICE JUNCTIONS OF THE DYSTROPHIN GENE AND THEIR THERAPEUTIC APPLICATIONS Download PDF

Info

Publication number
WO2003095647A3
WO2003095647A3 PCT/IT2003/000273 IT0300273W WO03095647A3 WO 2003095647 A3 WO2003095647 A3 WO 2003095647A3 IT 0300273 W IT0300273 W IT 0300273W WO 03095647 A3 WO03095647 A3 WO 03095647A3
Authority
WO
WIPO (PCT)
Prior art keywords
splice junctions
gene
therapeutic applications
antisense sequences
dystrophin gene
Prior art date
Application number
PCT/IT2003/000273
Other languages
French (fr)
Other versions
WO2003095647A2 (en
Inventor
Irene Bozzoni
Angelis Fernanda Gabriella De
Original Assignee
Univ Roma
Irene Bozzoni
Angelis Fernanda Gabriella De
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Roma, Irene Bozzoni, Angelis Fernanda Gabriella De filed Critical Univ Roma
Priority to AU2003231928A priority Critical patent/AU2003231928A1/en
Priority to DE60330136T priority patent/DE60330136D1/en
Priority to AT03749984T priority patent/ATE449170T1/en
Priority to EP03749984A priority patent/EP1501931B1/en
Priority to DK03749984.5T priority patent/DK1501931T3/en
Priority to SI200331749T priority patent/SI1501931T1/en
Publication of WO2003095647A2 publication Critical patent/WO2003095647A2/en
Publication of WO2003095647A3 publication Critical patent/WO2003095647A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it

Abstract

A gene is described that encodes for a snRNA modified such that it contains an antisense sequence complementary to at least one of the two splice junctions at 5´and/or 3´of one of the exons encoding for a protein of therapeutic interest, whose sequence should be skipped during the splicing process that converts the pre-mRNA to the mature mRNA. The gene is particularly advantageous which it contain segments complementary to both splice junctions. If introduced into appropriate vectors, the gene is useful in gene therapy, particularly in the treatment of Duchenne Muscular Dystrophies, dystrophic diseases.
PCT/IT2003/000273 2002-05-08 2003-05-06 CHIMERIC snRNA MOLECULES CARRYING ANTISENSE SEQUENCES AGAINST THE SPLICE JUNCTIONS OF THE DYSTROPHIN GENE AND THEIR THERAPEUTIC APPLICATIONS WO2003095647A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2003231928A AU2003231928A1 (en) 2002-05-08 2003-05-06 CHIMERIC snRNA MOLECULES CARRYING ANTISENSE SEQUENCES AGAINST THE SPLICE JUNCTIONS OF THE DYSTROPHIN GENE AND THEIR THERAPEUTIC APPLICATIONS
DE60330136T DE60330136D1 (en) 2002-05-08 2003-05-06 CHIMERIC SNRNA MOLECULES WITH ANTISENSE SEQUENCES AGAINST THE "SPLICE JUNCTIONS" OF THE DYSTROPHINE GENE AND THEIR THERAPEUTIC USES
AT03749984T ATE449170T1 (en) 2002-05-08 2003-05-06 CHIMERIC SNRNA MOLECULES WITH ANTISENSE SEQUENCES AGAINST THE ßSPLICE JUNCTIONSß OF THE DYSTROPHIN GENE AND THEIR THERAPEUTIC USES
EP03749984A EP1501931B1 (en) 2002-05-08 2003-05-06 Chimeric snrna molecules carrying antisense sequences against the splice junctions of the dystrophin gene and their therapeutic applications
DK03749984.5T DK1501931T3 (en) 2002-05-08 2003-05-06 Chimeric snRNA molecules that carry antisense sequences against the splicing compounds of the dystrophin gene and their therapeutic applications
SI200331749T SI1501931T1 (en) 2002-05-08 2003-05-06 Chimeric snrna molecules carrying antisense sequences against the splice junctions of the dystrophin gene and their therapeutic applications

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM2002A000253 2002-05-08
IT2002RM000253A ITRM20020253A1 (en) 2002-05-08 2002-05-08 SNRNA CHEMICAL MOLECULES WITH ANTISENSE SEQUENCES FOR SPLICING JUNCTIONS OF THE DYSTROPHINE GENE AND THERAPEUTIC APPLICATIONS.

Publications (2)

Publication Number Publication Date
WO2003095647A2 WO2003095647A2 (en) 2003-11-20
WO2003095647A3 true WO2003095647A3 (en) 2004-02-19

Family

ID=11456291

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT2003/000273 WO2003095647A2 (en) 2002-05-08 2003-05-06 CHIMERIC snRNA MOLECULES CARRYING ANTISENSE SEQUENCES AGAINST THE SPLICE JUNCTIONS OF THE DYSTROPHIN GENE AND THEIR THERAPEUTIC APPLICATIONS

Country Status (11)

Country Link
EP (2) EP2151497B1 (en)
AT (1) ATE449170T1 (en)
AU (1) AU2003231928A1 (en)
CY (1) CY1109746T1 (en)
DE (1) DE60330136D1 (en)
DK (1) DK1501931T3 (en)
ES (1) ES2336909T3 (en)
IT (1) ITRM20020253A1 (en)
PT (1) PT1501931E (en)
SI (1) SI1501931T1 (en)
WO (1) WO2003095647A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9139828B2 (en) 2008-05-14 2015-09-22 Prosensa Technologies B.V. Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means
US9243245B2 (en) 2007-10-26 2016-01-26 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
EP1555317B1 (en) 1998-03-20 2011-09-28 Commonwealth Scientific And Industrial Research Organisation Synthetic genes and genetic constructs comprising the same
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
AUPR621501A0 (en) 2001-07-06 2001-08-02 Commonwealth Scientific And Industrial Research Organisation Delivery of ds rna
WO2005026356A1 (en) * 2003-09-12 2005-03-24 Commonwealth Scientific And Industrial Research Organisation Modified gene-silencing nucleic acid molecules and uses thereof
FR2874384B1 (en) 2004-08-17 2010-07-30 Genethon ADENO-ASSOCIATED VIRAL VECTOR FOR PRODUCING EXON JUMP IN A GENE ENCODING A PROTEIN WITH DISPENSABLE DOMAINS
WO2007123391A1 (en) 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
EP1857548A1 (en) 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
DK2049664T3 (en) 2006-08-11 2012-01-02 Prosensa Technologies Bv Single-stranded oligonucleotides, complementary to repetitive elements, for the treatment of DNA repetitive instability-associated disorders
EP2152873A2 (en) * 2007-03-16 2010-02-17 Biorigen S.r.l Gene expression regulation technology and noncoding rnas for diagnosis and therapy
US8907075B2 (en) 2007-03-30 2014-12-09 Samuel Ian Gunderson Compositions and methods for gene silencing
WO2008121963A2 (en) * 2007-03-30 2008-10-09 Rutgers, The State University Of New Jersey Compositions and methods for gene silencing
US8343941B2 (en) 2007-03-30 2013-01-01 Rutgers, The State University Of New Jersey Compositions and methods for gene silencing
US9441221B2 (en) 2007-03-30 2016-09-13 Rutgers, The State University Of New Jersey Compositions and methods for gene silencing
WO2009008727A2 (en) 2007-07-12 2009-01-15 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs or tissues
WO2009008725A2 (en) 2007-07-12 2009-01-15 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs, tissues or tumor cells
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
NZ587178A (en) 2008-02-08 2011-11-25 Prosensa Holding Bv Methods and means for treating dna repeat instability associated genetic disorders
EP2396343B1 (en) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
AU2010239779A1 (en) 2009-04-24 2011-11-17 Prosensa Technologies B.V. Oligonucleotide comprising an inosine for treating DMD
EP2258863A1 (en) * 2009-05-25 2010-12-08 Universita'Degli Studi di Roma "La Sapienza" miRNA biomarkers for the diagnosis of duchenne muscular dystrophy progression, for monitoring therapeutic interventions, and as therapeutics
CA2785451C (en) 2009-12-24 2019-01-22 Prosensa Technologies B.V. Molecule for treating an inflammatory disorder
ES2683695T3 (en) 2010-01-12 2018-09-27 The University Of North Carolina At Chapel Hill Inverse restrictive terminal repeats for viral vectors
TWI541024B (en) 2010-09-01 2016-07-11 日本新藥股份有限公司 Antisense nucleic acid
EP2673289B1 (en) 2011-02-10 2023-05-03 The University of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
US9303258B2 (en) 2011-04-05 2016-04-05 The Regents Of The University Of California Method and compositions comprising small RNA agonist and antagonists to modulate inflammation
CA3120918A1 (en) 2012-01-27 2013-08-01 Biomarin Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
CN104797593B (en) 2012-09-28 2020-05-08 北卡罗来纳-查佩尔山大学 AAV vectors targeting oligodendrocytes
JP6396988B2 (en) 2013-03-15 2018-09-26 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル Methods and compositions for double glycan binding AAV vectors
EP3517612A1 (en) 2013-03-15 2019-07-31 The University of North Carolina At Chapel Hill Synthetic adeno-associated virus inverted terminal repeats
WO2016081811A1 (en) 2014-11-21 2016-05-26 The University Of North Carolina At Chapel Hill Aav vectors targeted to the central nervous system
JP6938377B2 (en) 2015-01-14 2021-09-22 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル Methods and compositions for targeting gene transfer
US10596247B2 (en) 2015-02-20 2020-03-24 Board Of Regents, The University Of Texas System Methods and compositions for attenuated chlamydia as vaccine and vector
IL299901A (en) 2015-09-28 2023-03-01 Univ Florida Methods and compositions for antibody-evading virus vectors
CN117801075A (en) 2017-03-15 2024-04-02 北卡罗来纳-查佩尔山大学 Polyploid adeno-associated virus vectors and methods of making and using same
JP2021519581A (en) 2018-04-03 2021-08-12 ストライドバイオ，インコーポレイテッド Viral vector to avoid antibodies
EA202092362A1 (en) 2018-04-03 2021-01-11 Страйдбайо, Инк. VIRAL VECTORS FOR TARGETING EYE TISSUE
BR112020020266A2 (en) 2018-04-03 2021-01-19 Stridebio, Inc. VIRUSES WITH ANTIBODY EVASION
CN112639110A (en) 2018-06-22 2021-04-09 阿斯克肋匹奥生物制药公司 Vectors for gene delivery to persist in cells
AU2020241888A1 (en) 2019-03-21 2021-09-30 Ginkgo Bioworks, Inc. Recombinant adeno-associated virus vectors
US20220194992A1 (en) 2019-04-26 2022-06-23 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding aav2.5 vector
AU2020367532A1 (en) 2019-10-17 2022-05-12 Ginkgo Bioworks, Inc. Adeno-associated viral vectors for treatment of Niemann-Pick disease type C
EP4010356A4 (en) 2020-10-28 2023-01-04 The University of North Carolina at Chapel Hill Methods and compositions for dual glycan binding aav2.5 vector
WO2022093769A1 (en) 2020-10-28 2022-05-05 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding aav2.5 vector
TW202242124A (en) 2021-01-14 2022-11-01 美商史崔德生物公司 Aav vectors targeting t-cells
EP4277644A1 (en) 2021-01-15 2023-11-22 Outpace Bio, Inc. Small molecule-regulated gene expression system
TW202342759A (en) 2022-02-04 2023-11-01 美商史崔德生物公司 Recombinant adeno-associated virus vectors, and methods of use thereof
TW202342070A (en) * 2022-03-30 2023-11-01 美商拜奧馬林製藥公司 Dystrophin exon skipping oligonucleotides
CN115806984B (en) * 2022-10-18 2023-10-10 昆明理工大学 Circular RNA and vector and application of vector

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1191097A1 (en) * 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induction of exon skipping in eukaryotic cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1191097A1 (en) * 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induction of exon skipping in eukaryotic cells

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BRUN C ET AL: "U7 snRNAs induce correction of mutated dystrophin pre-mRNA by exon skipping.", CMLS CELLULAR AND MOLECULAR LIFE SCIENCES, vol. 60, no. 3, March 2003 (2003-03-01), pages 557 - 566, XP009021235, ISSN: 1420-682X *
DE ANGELIS FERNANDA GABRIELLA ET AL: "Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Delta 48-50 DMD cells.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. UNITED STATES 9 JUL 2002, vol. 99, no. 14, 9 July 2002 (2002-07-09), pages 9456 - 9461, XP002261982, ISSN: 0027-8424 *
DEUTEKOM VAN J C T ET AL: "Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells", HUMAN MOLECULAR GENETICS, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 10, no. 15, 2001, pages 1547 - 1554, XP002250908, ISSN: 0964-6906 *
GORMAN ET AL.: "Restoration of Correct Splicing of Thalassemic ß-Globin Pre-mRNA by modified U1 snRNAs", J BIOL CHEM, vol. 275, no. 46, 17 November 2000 (2000-11-17), pages 35914 - 35919, XP002261981 *
M. MATSUO: "Duchenne and Becker Muscular Dystrophy: From Gene Diagnosis to Molecular Therapy", IUBMB LIFE, vol. 53, no. 3, March 2002 (2002-03-01), pages 147 - 152, XP009021242 *
MANN C J ET AL: "ANTISENSE-INDUCED EXON SKIPPING AND SYNTHESIS OF DYSTROPHIN IN THE MDX MOUSE", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 98, no. 1, 2 January 2001 (2001-01-02), pages 42 - 47, XP001160821, ISSN: 0027-8424 *
SUTER D ET AL: "DOUBLE-TARGET ANTISENSE U7 SNRNAS PROMOTE EFFICIENT SKIPPING OF AN ABERRANT EXON IN THREE HUMAN BETA-THALASSEMIC MUTATIONS", HUMAN MOLECULAR GENETICS, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 8, December 1999 (1999-12-01), pages 2415 - 2423, XP000973208, ISSN: 0964-6906 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9243245B2 (en) 2007-10-26 2016-01-26 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
US9499818B2 (en) 2007-10-26 2016-11-22 BioMarin Technologies, B.V. Methods and means for efficient skipping of at least one of the exons 51-53, 55, 57 and 59 of the human duchenne muscular dystrophy gene
US9528109B2 (en) 2007-10-26 2016-12-27 Biomarin Technologies B.V. Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mRNA
US9139828B2 (en) 2008-05-14 2015-09-22 Prosensa Technologies B.V. Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means

Also Published As

Publication number Publication date
AU2003231928A8 (en) 2003-11-11
DK1501931T3 (en) 2010-03-29
DE60330136D1 (en) 2009-12-31
EP2151497A3 (en) 2010-03-10
ITRM20020253A1 (en) 2003-11-10
EP1501931B1 (en) 2009-11-18
EP2151497B1 (en) 2014-01-08
ATE449170T1 (en) 2009-12-15
PT1501931E (en) 2010-02-23
ES2336909T3 (en) 2010-04-19
ITRM20020253A0 (en) 2002-05-08
WO2003095647A2 (en) 2003-11-20
EP2151497A2 (en) 2010-02-10
SI1501931T1 (en) 2010-03-31
CY1109746T1 (en) 2014-09-10
EP1501931A2 (en) 2005-02-02
AU2003231928A1 (en) 2003-11-11

Similar Documents

Publication Publication Date Title
WO2003095647A3 (en) CHIMERIC snRNA MOLECULES CARRYING ANTISENSE SEQUENCES AGAINST THE SPLICE JUNCTIONS OF THE DYSTROPHIN GENE AND THEIR THERAPEUTIC APPLICATIONS
WO2003040399A3 (en) Therapeutic methods for nucleic acid delivery vehicles
IL161584A0 (en) Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
WO2004098377A3 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
WO2008143668A3 (en) Indoleamine-2, 3-dioxygenase-2
HUP0004168A2 (en) Nucleotide sequences coding for the export of branched chain amino acids, process for isolating same and use of same
WO2003054154A3 (en) Antisense modulation of mucin 1, transmembrane expression
WO2003014306A3 (en) Antisense modulation of cholesteryl ester transfer protein expression
WO2003092612A3 (en) VECTORS HAVING BOTH ISOFORMS OF β-HEXOSAMINIDASE
AU4390099A (en) Nucleotide sequences of the apple lrpkm1 gene, encoded amino acid sequence and uses thereof
WO2005019259A3 (en) Variants of interleukin-1 receptor antagonist: compositions and uses thereof
WO2002006315A3 (en) Novel nucleic acid and amino acid sequences
EP1506216A4 (en) Antisense moodulation of kinesin-like 1 expression
IL169256A0 (en) Metalloprotease proteins
WO2003027229A3 (en) Antisense modulation of rip2 expression
AU2003294916A1 (en) Use of cis-99, trans-11 isomer of conjugated linoleic acid (cla) for treating inflammatory diseases
AU2001264845A1 (en) Nucleotide sequences encoding ramosa 1 gene and methods of use for same
WO2001092468A3 (en) Novel compositions for the expression of the human peptide histidine transporter 1 and methods of use thereof
HU0003279D0 (en) Process for preparation of metabolic products and nucleotide sequences encoding for the sod gene
WO2004015126A3 (en) Antisense modulation of edg1 expression
WO2005072092A3 (en) Systems for tightly regulated gene expression
AU2002211715A1 (en) Nucleic acid sequences encoding cmg proteins cmg proteins and methods for their use
WO2003040320A3 (en) Antisense modulation of human collapsin response mediator protein 2 expression
WO2002095022A3 (en) Sequence-specific dna binding compounds and their use in targeting telomeres and other dna sequences
AU2003255504A1 (en) Use of 6 amino-quinoline-5, 8 quinones and nucleic acids associated with senescence for the treatment of tumors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003749984

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003749984

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP